Early Movers in RNAi
Novartis AG has led a handful of Big Pharma into the potential new therapeutic modality of RNAi. Here we review those early moves in this nascent field, and take a look at which of the industry's big players has got game in RNAi. Sidebar to "Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps"
You may also be interested in...
SanoGene Therapeutics thinks it will be able to enhance outcomes for glioblastoma patients by following the unavoidable brain surgery with an injection of targeted plasmids containing short sequences of RNA.
Traversa aims to solve a fundamental problem: the adequate delivery of short interfering RNA molecules to a wide range of cell types via a non-cytoxic mechanism.
Dicerna Pharmaceuticals hopes to elude the IP fortresses of Alnylam and Merck with a license to RNA interference IP out of City of Hope's Beckman Research Institute. If successful, this adjacent doorway into RNAi could create a new option for those pharma companies that have thus far stayed on the sidelines of the RNAi game.